Lilly - TechWire

Lilly

2025.05.02

07:08

The three major U.S. stock indexes closed higher, with the S&P 500 and Dow Jones both recording eight consecutive daily gains

The three major U.S. stock indexes closed higher, with the Nasdaq up 1.52%, the S&P 500 up 0.63%, and the Dow up 0.21%. Among them, the S&P 500 and the Dow both recorded eight consecutive daily gains. Microsoft surged more than 7%, and the company's third quarter of fiscal year 2025 exceeded expectations across the board, with strong growth in cloud computing business. Meta rose more than 4%, Amazon rose more than 3%, Nvidia rose more than 2%, Google rose more than 1%, Apple and Netflix rose slightly; Tesla and Intel fell slightly. Eli Lilly fell more than 11%, the largest single-day drop since 2008.

2025.05.01

22:13

Eli Lilly (LLY.N) executives: The current tariff measures have not had a substantial impact on the company's financial outlook for 2025. The expansion of tariffs in other regions or the increase in retaliatory tariffs will have a negative impact on the industry.

18:46

Eli Lilly (LLY.N) reiterated its revenue guidance.

2025.04.29

11:29

Trump's first 100 days in office focus on corporate investment in the US

According to foreign media reports, CEOs of companies such as Nvidia, Johnson & Johnson, Eli Lilly, General Electric and SoftBank will visit the White House on the 30th local time. At that time, US President Trump will focus on introducing the investment plans of these companies in the United States announced within the first 100 days of his inauguration. According to people familiar with the matter, the White House has invited personnel from companies and investment funds in the defense, technology, healthcare and consumer goods industries to participate in the event, and the products of the participating companies will be displayed in the White House.

05:10

CEOs of Nvidia, Eli Lilly and others to visit White House on Wednesday

The CEOs of Nvidia, Eli Lilly and other companies will visit the White House on Wednesday.

2025.04.18

19:19

Eli Lilly CEO: Conduct research on Alzheimer's disease prevention and other brain diseases

Eli Lilly's CEO said that research on Alzheimer's disease prevention and other brain diseases will be carried out.

19:16

Eli Lilly CEO: It's important that we don't raise drug prices.

Eli Lilly's CEO said it's important that they don't raise drug prices.

17:39

Eli Lilly expects to submit orforglipron for weight management to global regulators by year end

On April 17, Eli Lilly announced the positive top-line results of the Phase 3 clinical study ACHIEVE-1, which evaluated the safety and efficacy of orforglipron versus placebo in patients with type 2 diabetes whose blood sugar control was still poor on the basis of diet control and exercise. Eli Lilly stated that Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist that successfully completed Phase 3 trials and is not restricted by diet or drinking. Eli Lilly expects to submit an application for orforglipron's use in weight management to global regulators by the end of this year, and expects to submit its application for the treatment of type 2 diabetes in 2026.

16:14

Morgan Stanley: Orforglipron, an oral weight loss drug, has become a driving force for stock prices, and Eli Lilly can still rise by another 34%

Morgan Stanley said that the oral weight loss drug Orforglipron has become a driving force for the stock price, and Eli Lilly can still rise by another 34%.

09:27

Diet drug concept stocks were active at the beginning of trading, and Jinkai Biosciences rose by more than 10%

Weight loss drug concept was active at the beginning of the session, with Jinkai Biosciences rising more than 10%, followed by Haofan Bio, Huadong Medicine, Hanyu Pharmaceutical, Baihua Pharmaceutical, Yipinhong, Changshan Pharmaceutical, etc. On the news front, Eli Lilly's oral weight loss drug Orforglipron had impressive Phase III clinical data, and its stock price rose by more than 14%.

2025.04.17

21:38

Novo Nordisk fell 8% in early trading

Novo Nordisk fell 8% in early trading after its weight loss drug competitor Eli Lilly achieved positive results in a Phase 3 trial of an oral weight loss drug.

21:30

U.S. stocks open: three major indexes rise and fall, Dow opens more than 1% lower

At the opening of the US stock market, the Dow Jones Industrial Average fell 1.23%, the S&P 500 rose 0.35%, and the Nasdaq rose 0.53%. TSMC rose more than 2%, and its Q1 net profit increased by 60% year-on-year, exceeding expectations. Eli Lilly rose 14%. The company released data on its weight loss drug study, and participants lost an average of 16 pounds at the highest dose. UnitedHealth fell 17% as the company lowered its annual profit forecast.

18:55

Eli Lilly (LLY.N) surged 13% in premarket trading after it released data on a study of its weight-loss drug.

18:54

Eli Lilly's US stock surged 13% before the market opened

Eli Lilly's U.S. shares surged 13% in premarket trading after it released data on a study of its weight-loss drug.

2025.03.31

17:54

Eli Lilly's new lipid-lowering drug data released can reduce genetic risk factors for heart disease by 94%

Eli Lilly and Company announced clinical data on its lipid-lowering drug lepodisiran at the American College of Cardiology meeting, showing that the highest dose of the drug reduced the level of genetic risk factors for heart disease by 94% in a mid-term trial.

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Apple (AAPL.O): Vietnam is expected to be the country of origin for most iPads, Macs, Apple Watches and Airpods sold in the United States.
                            2025-05-02

                                    US judge rules Apple violated order to reform App Store
                            2025-05-01

                                    Shanghai: Using tax support to encourage more innovation and help companies go global
                            2025-04-30

                                    Ideal Auto's Ring OS is officially open source, and the code is now available for download
                            2025-04-28

                                    Apple (AAPL.O) had a net profit of US$24.78 billion in the second quarter of fiscal year 2025, compared with market expectations of US$24.26 billion and US$23.636 billion in the same period last year.
                            2025-05-02